The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

July 15, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2022 (VIRTUAL)—Rheumatologists and patients alike often benefit from the recommendations produced by national and international professional societies that help synthesize the medical literature and provide guidelines for diagnosis and management of diseases. At the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR), updates of recommendation on anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA) were presented in a thorough and helpful manner.

You Might Also Like
  • ACR Updates COVID-19 Clinical Guidance for Adult Patients
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
  • 2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications
Explore This Issue
August 2022
Also By This Author
  • Dr. Michelle Petri: A Guiding Light for Patients with Lupus

ANCA-Associated Vasculitis

Dr. Hellmich

Bernhard Hellmich, MD, chair, Department of Medicine, Rheumatology and Immunology at the Medius Klinik Kirchheim, Kirchheim Unter Teck, Baden-Württemberg, Germany, began the session with an overview of recommendations for AAV. Dr. Hellmich noted that the prior sets of EULAR guidelines for the management of AAV, which came in 2008 and 2016, were in need of updating given new research and clinical developments in the field.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Several overarching principles for the recommendations on managing AAV include: 1) Patients with AAV should be offered the best care based on shared decision making between the patient and the physician considering efficacy, safety and costs; 2) patients should have access to education focusing on the impact and prognosis of AAV, including potential treatment-related complications; and 3) patients should be periodically screened for treatment-related adverse effects and comorbidities and be guided with prophylaxis and lifestyle modification recommendations to reduce complications and comorbidities.

In addition, AAV is rare, heterogeneous and potentially life- and organ-threatening, so multidisciplinary management is essential.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A new recommendation included using testing for both proteinase 3 (PR3) ANCA and myeloperoxidase (MPO) ANCA using a high-quality, antigen-specific assay—as opposed to indirect immunofluorescence—as the primary method of testing in patients with potential signs and/or symptoms of AAV.

A revised recommendation is that rituximab is now the preferred agent for treatment of patients with organ- or life-threatening AAV with relapsing disease.

The group also revised a recommendation on induction of remission in patients with non-organ- and non-life-threatening AAV and now note that rituximab, rather than methotrexate, should be the first-line agent. This is in part because treatment with methotrexate or another agent—mycophenolate mofetil—often leads to patients requiring higher doses of concomitant glucocorticoids.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

GPA & MPA

Another new recommendation uses the PEXIVAS trial to guide the quicker tapering of glucocorticoids for patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).1 PEXIVAS also evaluated the use of plasma exchange, and EULAR now recommends against plasma exchange for routine use in treating alveolar hemorrhage in patients with GPA/MPA. Plasma exchange can be considered for remission induction in patients with serum creatinine >300 µmol/L due to active glomerulonephritis.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis, Spondyloarthritis, Vasculitis Tagged With: ANCA-Associated Vasculitis, anti-neutrophil cytoplasmic antibodies (ANCA), axial spondyloarthritis (SpA), eosinophilic granulomatosis with polyangiitis (EGPA), EULAR, EULAR 2022, microscopic polyangiitis (MPA), Rheumatoid Arthritis (RA)Issue: August 2022

You Might Also Like:
  • ACR Updates COVID-19 Clinical Guidance for Adult Patients
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
  • 2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications
  • Good Flow: 2021 Updates in Vasculitis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)